EVERY DISEASE HAS ITS REMEDY *
Therapeutic Approach and Drug Development
We have developed a novel therapeutic concept based on a recombinant, genetically engineered enzyme with significantly enhanced activity.
* Paracelsus 1493-1541 – (Philippus Aureolus Theophrastus Bombastus von Hohenheim)
The resulting biopharmaceutical, BELACT, is intended for clinical use – subject to regulatory approval – in combination with a structured therapeutic protocol tailored for medical application.
SCALING UP PRODUCTION
Our drug substance manufacturing process is fully developed and ready for transition into industrial-scale production—laying the groundwork for clinical and commercial supply.
Characterization and Differentiation of Active Ingredients
BELACT exhibits significantly higher specific activity in enzymatic test systems – up to 15 to 300 times compared to known or potentially comparable active ingredients.
The enzyme was developed completely without animal-derived ingredients, leading to an improved safety profile and regulatory advantages. The underlying manufacturing process is patented and validated in all essential steps.
ADDRESSING UNMET NEEDS: FAMILIAL HYPERCHOLESTEROLEMIA
The BELACT therapy is aimed at patients with familial hypercholesterolemia – a genetically inherited condition that is inherited from one (heterozygous) or both parents (homozygous). Especially in the homozygous form, aggressive atherosclerosis and arteriosclerosis can occur in childhood, often unnoticed in the early stages.
BELACT has been developed for a genetically inherited condition that can lead to rapid vascular degradation in childhood, especially in homozygous cases. The disease promotes systemic lipid accumulation, inflammation, and plaque formation, leading to a high cardiovascular risk and early mortality.
Currently, there are no therapies that can reverse these advanced structural changes. BELACT fills this critical gap with a precisely targeted, biotechnological approach.
Discover the possibility: “Screening as an entry point to early intervention.”